University of Southern California/Norris Comprehensive Cancer Center

Los Angeles, California 90089

7 studies enrolling now · 44 studies all time

What they study most

AML, Active Idiopathic Inflammatory Myopathy, Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Aggressive Non-Hodgkin Lymphoma, Ampullary Cancer, Anaplastic Astrocytoma, Angiosarcoma, Antisynthetase Syndrome

Studies at this site

• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects — Recruiting now
• A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies — Recruiting now
• Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) — Recruiting now
• A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) — Recruiting now
• A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) — Recruiting now
• A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia — Recruiting now
• A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product — Recruiting now
• A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. — Completed
• Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma — Completed
• A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC — Running, not enrolling
• A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) — Running, not enrolling
• Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer — Completed
• A Longitudinal Observational Study of the Natural History and Management of Patients With HCC — Running, not enrolling
• An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG — Available (expanded access)
• Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer — Running, not enrolling
• Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway — Stopped early
• First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) — Running, not enrolling
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors — Running, not enrolling
• A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies — Stopped early
• Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) — Running, not enrolling
• A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers — Stopped early
• A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) — Stopped early
• CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) — Status unconfirmed
• Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer — Completed
• Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy — Completed
• A Study Of PF-04449913 Administered Alone In Select Solid Tumors — Completed
• TR1801-ADC in Patients With Tumors That Express c-Met — Paused
• Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer — Completed
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment — Status unconfirmed
• Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations — Completed
• Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients — Status unconfirmed
• (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive — Completed
• A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH — Completed
• AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer — Stopped early
• Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients — Stopped early
• KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera — Running, not enrolling
• ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases — Completed
• A Study of Fibrocaps™ in Surgical Bleeding — Completed
• Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery — Stopped early
• TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy — Stopped early
• Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors — Stopped early
• Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer — Completed
• A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers — Completed